Sandoz Canada Debuts Tecfidera Rival
Novartis Subsidiary Is Among First Approved Dimethyl Fumarate Generics
Sandoz has announced its launch of a generic rival to Tecfidera in Canada, with the firm among the first generics to be issued a notice of compliance by Health Canada.
You may also be interested in...
Blow For EU Tecfidera Rivals As Biogen Triumphs In Legal Battle
Developers of generic dimethyl fumarate have received a setback after a CJEU ruling in Biogen’s favor gave Tecfidera EU regulatory marketing protection until at least February 2024.
Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
Floodgates Open For Tecfidera Rivals
Following Mylan’s initial launch of a generic rival to Biogen’s $3.8bn Tecfidera brand, other generics companies are now following the firm into the US dimethyl fumarate market.